Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer

Peer Review reports

Original Submission
29 Apr 2013	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
Resubmission - Version 3
	Submitted	Manuscript version 3
4 Jun 2013	Reviewed	Reviewer Report - Wan-Teck Lim
5 Jun 2013	Reviewed	Reviewer Report - Balazs Halmos
20 Aug 2013	Author responded	Author comments - Michael Maitland
Resubmission - Version 4
20 Aug 2013	Submitted	Manuscript version 4
Publishing
12 Dec 2013	Editorially accepted
4 Jan 2014	Article published	10.1186/1471-2407-14-5

Back to article page